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Conversion of the host-encoded protease-sensitive cellular prion protein (PrPC) into the
scrapie-associated protease-resistant isoform (PrPSc) of prion protein (PrP) is the central event
in transmissible spongiform encephalopathies or prion diseases. Differences in transmissibility
and susceptibility are largely determined by polymorphisms in PrP, but the exact molecular
mechanism behind PrP conversion and the modulation by disease-associated polymorphisms is
still unclear. To assess whether the polymorphisms in either PrPC or PrPSc modulate the initial
binding of PrPC to PrPSc, several naturally occurring allelic variants of sheep PrPC and PrPSc that are
associated with differential scrapie susceptibility and transmissibility [the phylogenetic wild-type
(ARQ), the codon 136Val variant (VRQ) and the codon 171Arg variant (ARR)] were used.
Under cell-free PrP conversion conditions known to reproduce the observed in vivo differential
scrapie susceptibility, it was found that the relative amounts of PrPC allelic variants bound by
various allelic PrPSc variants are PrP-specific and have comparable binding efficiencies. Therefore,
the differential rate-limiting step in conversion of sheep PrP variants is not determined by the
initial PrPC–PrPSc-binding efficiency, but seems to be an intrinsic property of PrPC itself.
Consequently, a second step after PrPC–PrPSc-binding should determine the observed differences
in PrP conversion efficiencies. Further study of this second step may provide a future tool to
determine the mechanism underlying refolding of PrPC into PrPSc and supports the use of
conversion-resistant polymorphic PrPC variants as a potential therapeutic approach to interfere
with PrP conversion in transmissible spongiform encephalopathy development.
INTRODUCTION
Transmissible spongiform encephalopathy (TSE) diseases are
fatal neurodegenerative disorders and include (among others)
familial, sporadic and variant Creutzfeldt-Jakob disease in
humans, bovine spongiform encephalopathy (BSE) in cattle
and scrapie in sheep. TSEs (or prion diseases) are charac-
terized by the formation and accumulation of protease-
resistant prion protein (PrPSc) mainly in tissues of the central
nervous system. Formation of PrPSc is a post-translational
process and involves refolding (conversion) of the host-
encoded prion protein (PrPC) into partially protease-resistant
forms (PrPSc) (DeArmond & Prusiner, 2003).
Scrapie in small ruminants (e.g. sheep) is one of the best
documented models for natural TSE transmission. Poly-
morphisms in PrP have been shown to be of importance in
both interspecies and intraspecies transmissibilities (Bossers
et al., 2003). Susceptibility of sheep to scrapie seems mainly
dictated by polymorphisms in the gene encoding the prion
protein itself, and to date over 20 different naturally
occurring polymorphisms (only one mutation per allele) of
PrP have been described (Goldmann et al., 1990, 1991; Belt
et al., 1996; Bossers et al., 1996; Junghans et al., 1998; Elsen
et al., 1999; Thorgeirsdottir et al., 1999; Tranulis et al., 1999;
O’Rourke et al., 2000). The effects of polymorphisms in
ovine PrP on the relative susceptibility of sheep to scrapie
have been gauged in epidemiological studies of natural
scrapie outbreaks, in experimental transmissions to and
from sheep, and in cell-free conversion assays (Goldmann
et al., 1994; Bossers et al., 1996, 1997, 1999, 2000; Hunter
et al., 1996). Polymorphisms at sheep PrP aa 136, 154 and
171 have been shown to be most relevant in association with
differential TSE susceptibility. Several studies have shown
that an alanine at position 136, arginine at position 154
and glutamine at position 171 (ARQ) to be the phylogene-
tic wild-type (wt) PrP, with intermediate susceptibility
to scrapie. The polymorphism associated with increased
susceptibility to scrapie is the substitution of alanine with
valine at codon 136 (VRQ; 136V) and thus far the only
polymorphism shown to be associated with decreased
susceptibility or even resistance to natural scrapie is the
substitution of glutamine with arginine at codon 171 (ARR;
171R). Cell-free conversion of PrPC provides an excellent
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in vitro model, in which relative amounts of produced pro-
teinase K (PK)-resistant PrP reflect important biological
aspects of TSEs at the molecular level (Caughey et al., 1995;
Bossers et al., 1997, 2000, 2003; Raymond et al., 1997, 2000;
Bossers, 1999). In sheep scrapie, this technique has shown
that 136V and wt-PrPC are readily converted into PK-
resistant PrP by various types of PrPSc isolated from sheep
having different PrP genotypes. In contrast, 171R-PrP is
hardly converted into PK-resistant PrP (Bossers et al., 1997,
2000, 2003; Bossers, 1999; Raymond et al., 2000).
Studies on the conversion of hamster and mouse PrPC
isoforms resulted in indications that diminished acquisi-
tion of PK resistance is not due to lack of binding of PrPC to
PrPSc (Horiuchi et al., 2000). However, no data on bind-
ing efficiencies of ovine PrPC to PrPSc are available to date.
Furthermore, whereas differences in susceptibility of- and
transmissibility in sheep can entirely be explained at the
molecular level by the effects of single polymorphisms
in PrPC or PrPSc on PrP conversion, the exact molecular
mechanism determining these differences is still unknown
(Bossers et al., 2000; Dubois et al., 2002; Tranulis, 2002;
Sabuncu et al., 2003).
In the present study, sheep scrapie susceptibility-linked
polymorphisms were used to determine whether differential
binding efficiencies of sheep PrPC to PrPSc determine the
observed differential conversion efficiencies of sheep PrP
(Bossers et al., 1997, 2000; Raymond et al., 1997, 2000).
METHODS
PrPC constructs and expression. The three sheep PrPC variants
used (136V, wt and 171R) were cloned, expressed and characterized
as described previously (Bossers et al., 1997). Briefly, PrP open read-
ing frames (ORF) were subcloned into the eukaryotic expression
vector pECV7. The vectors containing PrP ORF were stably trans-
fected into Chinese hamster ovary (CHO) cells. High and stable
expressing single-cell-clones were selected by immunoperoxidase
monolayer assay and Western blotting, using rabbit anti-peptide
antiserum R521-7 (van Keulen et al., 1995).
Radiolabelling and purification of PrPC. Radiolabelling and
purification of the three PrPC variants were performed as described
previously (Raymond et al., 1997; Bossers et al., 2000). Briefly, single
cell clones expressing the different PrPC variants were starved for
30–60 min in label medium and subsequently labelled with 1 mCi
(37 MBq) [35S]methionine/cysteine TRAN35S-label (ICN Biomedicals).
Cells were lysed in lysis buffer containing Triton X-100 (0?5 %; ICN
Biomedicals) in the presence of protease inhibitors (1 nM Pefabloc
SC, 1 nM leupeptine, 1 nM pepstatin and 0?15 nM aproprotin). 35S-
labelled PrPC was immunopurified by PrP-specific antiserum R521-7
captured by protein A–Sepharose (10 % w/v), which was eluted in
0?1 M acetic acid.
Radiolabelling and purification of classical swine fever virus
(CSFV) glycoprotein E2. For labelling, an expression vector con-
taining the gene encoding glycoprotein E2 of CSFV transfected into
SK6 cells (van Gennip et al., 2002) was used. Radiolabelling and
purification of E2 were essentially performed as described above,
albeit on a larger scale. 35S-labelled E2 was immunopurified using
monoclonal antibody V3 (Wensvoort, 1989) and eluted in 0?1 M
acetic acid.
PrPSc purification and analysis. PrPSc was isolated from brain
tissue of clinically ill scrapie sheep with either homozygous alleles
for 136V-PrP or wt-PrP. PrP genotypes were determined by Sanger
sequencing of the full PrP ORF as described previously (Bossers et al.,
1996). PrPSc was purified by ultracentrifugational pelleting from
Sarkosyl-homogenated brains as described previously (Caughey et al.,
1995; Bossers et al., 1997). The final pellets were sonicated in PBS
containing 1?0 % zwitter-reagent (SB 3-14). Yields of PrPSc were
quantified by SDS-PAGE (12 % NuPAGE; Invitrogen) and Western
blotting using antiserum R521-7.
Conversion-binding assay. Conversion and binding efficiencies
were determined by double volume cell-free conversion reactions
essentially as described previously (Horiuchi et al., 2000; Priola &
Lawson, 2001) and adapted to ovine cell-free conversion conditions
as used before (Caughey et al., 1995; Bossers et al., 1997, 2000).
Briefly, PrPSc was partially denatured in 2?5 M guanidinium-hydro-
chloride (GdnHCl) for at least 2?5 h at 37 uC. Aliquots of denatured
PrPSc (2–4 mg per reaction) were mixed with 10 000–20 000 c.p.m.
purified 35S-labelled PrPC (~20–40 ng 35S-labelled PrPC) and
further diluted to a final concentration of 1?0 M GdnHCl in conver-
sion buffer (50 mM sodium citrate, pH 6?0, 5 mM cetylpyridinium
chloride, 1 % N-lauroylsarcosine and protease inhibitors). Reactions
were incubated for 3 days at 37 uC (or shorter for the kinetic experi-
ments). After incubation, the reaction volume was split in two equal
aliquots in separate siliconized tubes. One aliquot was used for
binding analysis and centrifuged for 30 min at 17 500 g at room tem-
perature, the supernatant was transferred to a separate siliconized
tube (unbound fraction) and the pellet (bound fraction) dissolved
in 1 % SDS by sonication. From the second aliquot, 1/10 volume
was transferred to a separate siliconized tube (reference fraction)
and the remaining 9/10 volume was treated with 35 mg PK ml21 for
1 h at 37 uC. PK was inactivated by the addition of Pefabloc-SC
(Roche).
All the samples were methanol-precipitated and the pellet was dried
and dissolved in Laemmli SDS-PAGE sample buffer containing 5 %
(v/v) 2-mercaptoethanol and 4 M urea. Samples were run on SDS-
PAGE (12 % NuPAGE; Invitrogen), the dried gels were visualized by
phosphorimaging and analysed using a STORM-840 imager and the
ImageQuant 5.1 software (Molecular Dynamics). Binding percentages
were calculated by dividing the amount of labelled PrPC (molecular
mass between 24 and 28?5 kDa) of each fraction [pellet (p) and
supernatant (s)] by the total amount of labelled PrPC (p+s). Con-
version percentages were calculated by dividing the amount of labelled
PrP left after PK digestion (molecular mass between 19 and 21?5 kDa)
by the amount of labelled PrPC in the reference fraction (molecular
mass between 24 and 28?5 kDa).
Statistical analysis of binding efficiencies. Statistical calcula-
tions were performed using the GenStat 6.1 program. To compen-
sate for differences in possible variance as a result of a fixed scale,
variance stabilizing angular transformation of the binding percentages
was utilized (section 4?1?3; McCullagh, 1983). Absolute amounts of
bound 35S-labelled PrPC varied, probably as a result of the aggre-
gated state of the PrPSc isolate used; therefore binding patterns were
compared by the analysis of variance method to determine whether
significant differences occurred in these binding patterns. Com-
parisons of binding patterns were made separately for the three PrPC
variants and for the two different PrPSc isolate groups. In order to
determine significant differences in binding patterns, the least signif-
icant difference (LSD; the minimum amount needed to demonstrate
a significant difference) was calculated and compared with the
observed differences between the mean binding percentages for
either the PrPC variants or the PrPSc isolate groups.
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RESULTS
Binding efficiencies of PrPC to PrPSc
In total, six independent PrPSc isolates from six sheep
homozygous for 136V-PrPC and six independent PrPSc
isolates from six sheep homozygous for wt-PrPC were
isolated and tested for binding affinities to three natural
allelic variants of sheep PrPC; 136V-PrPC (VRQ), wt-PrPC
(ARQ) and 171R-PrPC (ARR). At least two independent
reaction duplicates were analysed from each PrPSc isolate.
Binding efficiencies of the individual PrPSc isolates were
determined using the conversion-binding assay, in which
cell-free conversion conditions used were identical to pre-
vious studies, showing significant differential conversion of
sheep PrPC variants (Bossers et al., 2000). Because aggregates
were pelleted by spinning for 30 min at 17 500 g, we needed
to take into account that not all of the PrPSc is actually
pelleted at this ‘low’ speed. However, most of the PrPSc was
pelleted (~86?4 % of the total input). Therefore, it can be
assumed that the amount of 35S-labelled PrPC found in the
pellet fraction is representative of most if not all of the actual
bound 35S-labelled PrPC. The addition of PrPSc, isolated
from sheep homozygous for 136V-PrP (Fig. 1a) or isolated
from sheep homozygous for wt-PrP (Fig. 1b), resulted in
recovering most of the labelled PrPC in the bound pellet (p)
fraction (Fig. 1a and b, lanes 1, 3 and 5) and only a small
amount of labelled PrPC remained in the unbound super-
natant (s) fraction (Fig. 1a and b, lanes 2, 4 and 6) for each
PrPC tested (Table 1; 136V-PrPSc and wt-PrPSc isolates).
Fig. 1. Phosphorimage of SDS-PAGE showing an example of
binding assay samples obtained with PrPSc isolated from a sheep
homozygous for 136V-PrP allele (a) or from a sheep homozygous
for wt-PrP allele (b). Lanes containing 14C-marker (Amersham
Biosciences) are marked ‘m’, sizes of the marker bands are 30
and 21?5 kDa. Non-glycosylated PrP is indicated by the 27 kDa
marker. Lanes 1 and 2 represent results with 136V-PrPC, lanes 3
and 4 represent results with wt-PrPC and lanes 5 and 6 represent
results with 171R-PrPC of which the odd lanes contain the pel-
leted (bound) fraction (p) and the even lanes contain the superna-
tant (unbound) fraction (s).
Table 1. Mean percentages of bound 35S-labelled PrPC determined for PrPSc isolates from sheep
Isolate Type* nD Mean binding (%) PrPCd Mean binding (%)
PrPSc isolate group
136V±SEM ARQ±SEM 171R±SEM ±SEM
553237 136V 3 83?3±11?6 91?3±2?7 89?4±2?1
558998 136V 6 89?2±2?8 86?4±5?4 89?7±5?3
577275 136V 2 97?0±0?5 98?4±0?5 89?2±2?5 86?2±1?7
601936 (343) 136V 3 81?9±8?5 83?7±4?6 91?1±1?5
606316 136V 4 86?3±2?2 74?5±4?8 84?1±4?2
609619 136V 5 84?0±1?1 67?5±4?4 85?7±0?4
514076 wt (ARQ) 3 88?1±4?7 81?2±10?7 88?9±9?1
523900 wt (ARQ) 4 80?1±5?3 85?0±6?9 70?3±9?8
532643 wt (ARQ) 2 89?2±2?3 86?5±3?9 74?3±19?7 87?3±1?8
577331 wt (ARQ) 3 91?0±1?6 87?6±6?0 85?2±4?1
603397 wt (ARQ) 3 87?9±7?2 87?4±1?4 93?5±1?0
614116 wt (ARQ) 2 97?9±1?4 98?8±0?3 98?2±0?8
Mean binding (%) PrPC variant 88?0±1?6 85?6±2?5 86?6±2?2
*PrPSc isolated from sheep with a homozygous allele for either 136V-PrPC or wt-PrPC.
DThe number of repeated (independent) reactions for each PrPSc isolate.
dAbsolute amounts of bound 35S-labelled PrPC ranged from ~60 to 99 %, depending on the aggregated
state of a PrPSc isolate. Therefore, analysis of variance on the observed binding patterns between PrPC
variants and PrPSc isolate groups was performed.
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Comparison between repeated measurements of a PrPSc
isolate or between different PrPSc isolates showed that the
absolute amount of bound PrPC was linked to the isolated
batch of PrPSc [probably due to differences in preparation
of PrPSc aliquots (sonication) or ‘age’ of an isolate]. There-
fore, the absolute binding percentages (per measurement) of
bound 35S-labelled PrPC were not compared, but rather
the mean binding percentages of repeated measurements
(Table 1).
Binding percentages were compared by variance analysis,
after variance stabilizing angular transformation of the
binding percentages. Firstly, binding patterns were com-
pared between the PrPC variants and no significant differ-
ences were found (Fig. 2a) since the LSD between PrPC
variants was calculated to be 4?5 %, which was higher
than the maximum difference of 2?4 % between the mean
binding percentages of 136V-PrPC, wt-PrPC and 171R-PrPC
(88?0±1?6, 85?6±2?5 and 86?6±2?2 %, respectively).
Secondly, binding patterns were compared between the
PrPSc groups and again no significant differences were
shown (Fig. 2b) since the LSD between PrPSc variants was
5?8 %, which is again higher than the maximum difference
of 1?1 % between the mean binding percentages for the
wt/wt (homozygous wt-PrP) and 136V/136V (homozygous
136V-PrP) PrPSc isolate groups (86?2±1?7 and 87?3±1?8 %,
respectively).
To gain insight into the dynamics of the binding reaction,
binding percentages were also determined at shorter
incubations (1 h, 1 day, 2 days and the standard 3 days).
At each time point, binding percentages were determined of
the three PrPC variants to PrPSc (n=4; two wt/wt and two
136V/136V isolates). No significant differences were found
between the three PrPC variants and the overall mean
binding percentages at the four time points (Fig. 3).
Binding specificity of PrPSc to PrPC
In order to exclude potential non-specific binding or aggre-
gation features of PrPC, we performed several controls. First
of all, 35S-labelled PrPC was incubated without addition of
PrPSc to determine whether ‘self aggregation’ and sponta-
neous pelleting of PrPC occurred. Exclusion of PrPSc, by
replacing with demineralized water (SQ), did not result in
significant amounts of 35S-labelled PrPC in the pellet frac-
tion, leaving on average 93?6±1?3 % of the 35S-labelled
PrPC variants in the supernatant fraction (Fig. 4a, lanes 1
and 2). Therefore, self-aggregation of PrPC is not responsible
for recovering significant amounts of labelled PrPC in the
pellet. Furthermore, it shows that the presence of aggregated
protein (PrPSc) is a prerequisite for pelleting 35S-labelled
PrPC under conditions maintaining cell-free conversion
specificity.
To determine whether 35S-labelled PrPC could be non-
specifically ‘captured’ and pelleted by any aggregated pro-
tein, PrPSc was replaced in the binding assay with keyhole
limpet haemocyanin (KLH), a very large mainly aggregated
Fig. 2. Boxplots of binding patterns after angular transformation
of binding percentages. The binding percentages have been
plotted against the PrPC variants (a) and PrPSc isolate groups (b).
The boxplot shows the total spread of all determined binding per-
centages, with the box representing 95% of all measurements
and the line in the box representing the mean value of the mea-
surements. Analysis of variance of the binding percentages shows
that neither the PrPC variant nor the PrPSc isolate group have a
significant effect on the binding patterns obtained.
Fig. 3. Kinetics of the binding efficiencies of the three PrPC
variants to PrPSc homozygous 136V and homozygous wt. Mean
binding percentages for each PrPC variant are indicated includ-
ing the error bars (SEM) for the repeated experiments after incu-
bation for the indicated time.
2630 Journal of General Virology 86
A. Rigter and A. Bossers
protein. A surplus of KLH was added (about 5 mg per reac-
tion) to favour KLH aggregation. No significant amounts of
35S-labelled PrPC were detected in the pellet fraction. On
average 94?3±2?3 % of the 35S-labelled PrPC remained in
the unbound fraction (Fig. 4a, lanes 3 and 4), which is about
the same as the amount of PrPC in the pellet fraction of
assays without any aggregated protein (see above). To
ensure that KLH remained aggregated under the specific
conversion conditions used, soluble and pellet fractions
were also analysed on SDS-PAGE by total protein staining
(Sypro Orange; Molecular Probes). On average 79?8±1?0 %
of the added KLH was recovered in the pellet fraction
(Fig. 4b, lanes 1 and 2), which is comparable to the per-
centage of aggregation determined for KLH (75?9±2?1 %) in
storing buffer (0?1 M sodium phosphate buffer, pH 7). Since
no increase in PrPC pelleting was observed, and although
only one other aggregated protein was tested for non-specific
capture of PrPC, this indicates that 35S-labelled PrPC is
probably not a ‘sticky’ protein binding to any aggregate.
To determine whether 35S-labelled PrPC could non-
specifically bind to other large soluble proteins, resulting
in significant amounts of precipitation, PrPSc was replaced
by thyroglobulin (TG), a large unrelated soluble protein
frequently used as a carrier in protein precipitation metho-
dologies. A surplus of TG was added (about 5 mg per reac-
tion) but no significant amounts of 35S-labelled PrPC were
detected in the pellet fraction; on average 90?6±2?6 %
remained in the supernatant fraction (Fig. 4a, lanes 5 and
6). To ensure that TG remained largely soluble under the
specific conversion conditions used, soluble and pellet
fractions were also analysed on SDS-PAGE by total pro-
tein staining (Sypro Orange). On average 94?4±2?5 % of
the TG remained in the supernatant (Fig. 4b, lanes 3 and 4)
under the specific conversion conditions used. Even though
only one large soluble protein was tested, this indicates that
35S-labelled PrPC is not significantly precipitated by binding
to any other large soluble heterologous protein like TG.
To determine whether any labelled soluble protein would
bind to the added aggregated PrPSc, 35S-labelled PrPC was
replaced with 35S-labelled E2 of CSFV, an unrelated but
similarly processed protein (membrane bound partially N-
glycosylated protein of about 51–54 kDa). No significant
amounts of 35S-labelled E2 protein were found in the bound
fraction, while 91?9±3?5 % of the 35S-labelled E2 protein
remained in the unbound fraction (Fig. 4c, lanes 1 and 2).
This indicates that binding of 35S-labelled PrPC by PrPSc is
PrP-specific.
In summary, we have shown that PrPC binds efficiently to
PrPSc with no significant differences in binding patterns
between PrPC variants and PrPSc isolate groups, under con-
ditions maintaining cell-free conversion specificity (Fig. 5).
Furthermore, we have shown that PrPC does not sponta-
neously aggregate due to the specific conversion condition
used, does not stick to unrelated aggregated protein like
Fig. 4. Examples of control reactions for determining specificity
of PrPC–PrPSc interaction within the binding assay. (a)
Phosphorimage of SDS-PAGE (indicated in pseudo intensity
staining) analysis of samples obtained when PrPSc was
replaced with either water (SQ; lanes 1 and 2), KLH (lanes 3
and 4) or TG (lanes 5 and 6). (b) Sypro Orange total protein
staining of SDS-PAGE (indicated in pseudo intensity staining)
containing conversion/binding samples having KLH (lanes 1
and 2) and TG (lanes 3 and 4) instead of PrPSc under the
specific conversion conditions used. (c) Phosphorimage of
SDS-PAGE (indicated in pseudo intensity staining) containing
samples obtained when 35S-labelled PrPC was replaced with
35S-labelled E2 protein of CSFV. All odd lanes contain the pel-
leted (p) (bound) fraction and all even lanes contain the super-
natant (s) (unbound) fraction.
Fig. 5. Observed relative normalized conversion efficiencies of the
combined conversion-binding reactions. Reactions were normal-
ized to the most efficient homologous reactions. (a) Conversion
efficiencies of the three PrPC variants induced by 136V-PrPSc.
(b) Reactions induced by wt-PrPSc. Mean normalized efficiencies
and the corresponding error bars (SEM) are indicated.
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KLH and does not precipitate with other large soluble pro-
teins like TG. Additionally, we have shown that PrPSc does
not bind to unrelated labelled soluble protein (E2). There-
fore, we can conclude that PrPSc-associated pelleting of 35S-
labelled PrPC represents a PrPC–PrPSc-specific interaction
and that addition of aggregated protein (PrPSc) is a pre-
requisite for pelleting 35S-labelled PrPC under conditions
maintaining cell-free conversion specificity. Since no differ-
ences were detected in the binding patterns of the tested
PrPC variants to the different PrPSc isolates, the rate-limiting
step determining the observed differential conversion effi-
ciencies of PrPC variants has to be during a subsequent step
in the conversion after binding of PrPC to PrPSc (Fig. 6).
DISCUSSION
The aim of this study was to gain insight into the mechanism
underlying the modulation of sheep scrapie susceptibility
by polymorphisms in PrPC or PrPSc. Bossers et al. (2000)
showed that the in vitro conversion assay is a representative
tool for assessing modulating effects of scrapie-associated
polymorphisms. Other studies have shown that the con-
version of PrPC by PrPSc is induced by the aggregated forms
of PrPSc (Caughey et al., 1995, 1997). These aggregates can
be pelleted by high-speed centrifugation. The amount of
35S-labelled PrPC that is bound by PrPSc and subsequently
recovered from the pellet should give an indication of
whether the disease-associated polymorphisms modulate
binding of PrPC by PrPSc or whether these polymorphisms
have their modulating effects in a subsequent step after the
initial binding during the conversion.
By applying a conversion-binding assay (Horiuchi et al.,
2000), binding efficiencies of sheep PrPC variants to sheep
PrPSc variants have been measured. Since no significant
differences in binding efficiencies were measured between
any of the variants, the initial binding efficiencies cannot
account for the observed differential conversion efficiencies
of sheep scrapie susceptibility-linked variants of PrP. We
show for instance that 171R-PrPC binds to PrPSc as efficiently
as 136V-PrPC or wt-PrPC, whereas conversion efficiencies
differ remarkably. Therefore, a second (or) further step in the
conversion process, in which the disease-associated poly-
morphisms have their modulating effect, seems to be involv-
ed in the conversion of the PrP protein (Fig. 6). These
findings are corroborated by a study in which interactions
between heterologous forms of prion protein have been
studied in vitro using mouse and hamster PrP isoforms
(Horiuchi et al., 2000), in which is shown that PrPC of
different species (hamster and mouse) bind equally efficiently
to PrPSc of mouse while preserving conversion specificity,
also indicating that a second step in the conversion after
initial binding should determine the species specificity.
In this study, we also show that PrPC does not precipitate
spontaneously, does not stick to unrelated aggregated
protein (KLH), and does not precipitate with other large
soluble proteins (TG). In addition, we showed that PrPSc
does not bind unrelated labelled soluble protein CSFV E2.
Therefore, we conclude that PrPSc-associated pelleting of
35S-labelled PrPC represents a PrPC–PrPSc-specific interac-
tion and that addition of aggregated PrPSc is a prerequisite
for pelleting 35S-labelled PrPC under conditions maintain-
ing cell-free conversion specificity. These results are in
conjunction with results in which no spontaneous PK-
resistant PrP was formed under the cell-free conversion
conditions when PrPSc was replaced by SQ water (Bossers
et al., 1997, 2000). The inability of PrPSc to significantly
bind 35S-labelled E2 additionally confirms that binding of
35S-labelled PrPC to PrPSc is PrP-specific and does not solely
Fig. 6. Schematic representation of PrPC
conversion. (a) Conversion of homologous,
conversion prone PrPC (wt, 136V): efficient
binding (i), highly efficient conversion (ii) and
‘re-seeding’ (iii) possible. (b) Conversion of
heterologous, conversion prone PrPC
(wt, 136V): efficient binding (i), efficient con-
version (ii) and ‘re-seeding’ (iii) possible.
(c) Conversion of heterologous, conversion-
resistant PrPC (171R): efficient binding (i),
highly inefficient or blocked conversion
(ii) and ‘re-seeding’ (iii) possibly blocked.
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depend on post-translational modifications or non-specific
‘sticky’ properties of PrP.
Since 171R-PrPC seems to bind as efficiently to PrPSc as
wt-PrPC and 136V-PrPC, the 171R-PrPC variant may be
valuable in firstly, providing clues for designing new thera-
peutic strategies by determination of the mechanism
underlying the refolding process of PrPC into PrPSc, for
example, by using the 171R-PrPC variant to determine sites
involved in binding and/or conversion or by comparing
protein properties (i.e. stability, unfolding/refolding kinet-
ics). Secondly, since conversion-resistant 171R-PrPC binds
efficiently to PrPSc it may provide a future tool to block
prion conversion through direct interference or blocking
of PrPSc polymer growth as hypothesized before by Bossers
et al. (1999). In addition, results from literature show that
heterozygosity for PrP is a protective factor against TSE
development as demonstrated by studies in vitro (Priola
et al., 1994; Holscher et al., 1998; Horiuchi et al., 2000) or
in vivo for sheep (Goldmann et al., 1994; Belt et al., 1995;
Clouscard et al., 1995; Bossers et al., 1996; Hunter et al.,
1996) and humans (Collinge et al., 1991; Palmer et al., 1991).
This is in conjunction with our results showing that various
differentially converting PrPC variants bind equally effi-
ciently to PrPSc but have different conversion efficiencies. In
heterozygotes, this ‘inhibition’ of conversion by heterol-
ogous PrP variants might explain why heterozygotes have
longer incubation times than their homozygous counter-
parts. This is corroborated by the fact that resistance in
heterozygous sheep is not caused by preferential allelic use
(Caplazi et al., 2004).
The coupled in vitro cell-free conversion efficiencies (Fig. 5)
reflect results as described before (Bossers et al., 2000),
where susceptibility to scrapie was linked to the modulating
effects of polymorphisms on the conversion of sheep PrP.
In addition to these in vitro cell-free conversion assays, PrP
polymorphisms have been shown to tightly control sheep
prion replication in cultured cells (Sabuncu et al., 2003).
Furthermore, it has been shown that polymorphisms in PrP
determine both interspecies and intraspecies transmissibil-
ities (Bossers, 1999; Bossers et al., 2003) and/or the stability
of the PrPC molecule itself (Rezaei et al., 2002).
By correlating conversion- and binding-patterns, we showed
that 171R-PrPC binds to PrPSc as efficiently as conver-
sion prone variants like wt (ARQ) and 136V-PrPC. Since
naturally occurring polymorphisms of sheep PrPC seem not
to have a significant modulating effect on the initial binding
of PrPC to PrPSc, these could somehow modulate a sub-
sequent step in the conversion process (Fig. 6). Both 136V
and 171R are polymorphisms that affect PrPC stability
and are close to the region that supposedly is involved in
refolding of PrPC to PrPSc (Rezaei et al., 2002; Eghiaian et al.,
2004). This region is composed of the two small b-sheets
[sheep aa 129–134 (S1) and 163–167 (S2)], which are
the positions from where the first a-helix [aa 146–158 (H1)]
is converted into an anti-parallel organized b-sheeted struc-
ture. It could also be that the 171R polymorphism results in
increased protease sensitivity of 171R-PrPC itself due to
destabilization of the PrPC molecule (Rezaei et al., 2002),
thus resulting in slower amyloidogenesis because the 171R-
PrPC molecule could internalize and be degraded by the
PrP-expressing cell more rapidly than the other variants
before the actual polymerization can take place. In contrast,
the 136V polymorphism could stabilize the PrPC molecule,
resulting in an elongation of the survival of 136V-PrPC and
thereby supporting the subsequent conversion.
Since disease-associated polymorphisms of sheep PrP do not
have an effect on binding properties of PrPC to PrPSc,
dominant-negative inhibition of the 171R polymorphism
on prion conversion (Bossers, 1999; Bossers et al., 1999,
2000; Perrier et al., 2002) is therefore not due to lack of
interaction between PrP variants as suggested by Perrier
et al. (2002), but more probably due to a more subtle mode
of modulation by the PrP polymorphism on the conversion
or on the interaction with chaperone proteins under natural
conditions.
This study shows that the interaction between PrPC and
PrPSc in the conversion-binding assay is PrP-specific. Whe-
ther PrPC binds to the so-called nucleation site of PrPSc only
or whether it can bind to other sites of PrPSc aggregates is
under investigation. The next logical step, currently under
investigation, is to find out whether conversion-resistant
(natural or artificial) PrP variants can effectively interfere
with the process of PrP conversion and thereby therapeu-
tically block or significantly delay TSE development.
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